Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes

被引：12

作者：

Bannerji, Rajat ^{[1
]}

Arnason, Jon E. ^{[2
]}

Advani, Ranjana ^{[3
]}

Brown, Jennifer R. ^{[4
]}

Allan, John N. ^{[5
]}

Ansell, Stephen M. ^{[6
]}

Barnes, Jeffrey ^{[7
]}

O'Brien, Susan M. ^{[8
]}

Chavez, Julio C. ^{[9
]}

Duell, Johannes ^{[10
]}

Lowy, Israel ^{[11
]}

Charnas, Robert ^{[11
]}

Sternberg, David ^{[11
]}

Ambati, Srikanth ^{[11
]}

Adriaens, Lieve ^{[12
]}

Ufkin, Melanie ^{[11
]}

Yan, Xiaoyu ^{[11
]}

Li, Jingjin ^{[12
]}

Navarro, Mark ^{[11
]}

Gasparini, Peter ^{[11
]}

Jankovic, Vladimir ^{[11
]}

Fiaschi, Nathalie ^{[11
]}

Zhang, Wen ^{[11
]}

Hamon, Sara ^{[11
]}

Thurston, Gavin ^{[11
]}

Topp, Max S. ^{[10
]}

机构：

[1] Canc Inst New Jersey, New Brunswick, NJ USA

[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[3] Stanford Univ, Stanford, CA 94305 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Weill Cornell Med, Div Hematol & Oncol, New York, NY USA

[6] Mayo Clin, Div Hematol, Rochester, MN USA

[7] Massachusetts Gen Hosp, Boston, MA 02114 USA

[8] Univ Calif Irvine, Irvine, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[10] Univ Hosp Wurzburg, Wurzburg, Germany

[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[12] Regeneron Pharmaceut Inc, Basking Ridge, NJ USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113328

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1690

引用

页数：5

共 50 条

[21] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
Sacchi, S
Federico, M
Dastoli, G
Fiorani, C
Vinci, G
Clò, V
Casolari, B
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25
[22] Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma
McLinden, Gretchen P.
Avery, Anne C.
Gardner, Heather L.
Hughes, Kelley
Rodday, Angie M.
Liang, Kexuan
London, Cheryl A.
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (03) : 1666 - 1674
[23] Anti-CD20 therapy for older patients with B-cell non-Hodgkin lymphoma in the context of epidemic normalization
Zhang, Dongdong
Xu, Shuangnian
ASIAN JOURNAL OF SURGERY, 2024, 47 (07) : 3290 - 3292
[24] Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma
Galanina, Natalie
Jasielec, Jagoda
Peace, David
Smith, Sonali M.
Nabhan, Chadi
LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 752 - 753
[25] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Earl, Christian Tyler
Wilding, Emily
Quinion, Carl
Lustberg, Mark
Benson, Don M., Jr.
Jones, Jeffrey A.
Byrd, John C.
Wegener, William A.
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
BLOOD, 2010, 116 (21) : 1148 - 1149
[26] Anemia in diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) patients
Gallagher, C. L.
Glinert, K. D.
Kohut, I. F.
Henry, D. H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[27] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
Bannerji, Rajat
Allan, John N.
Arnason, Jon E.
Brown, Jennifer R.
Advani, Ranjana
Ansell, Stephen M.
O'Brien, Susan M.
Duell, Johannes
Martin, Peter
Joyce, Robin M.
Li, Jingjin
Flink, Dina M.
Zhu, Min
Weinreich, David M.
Yancopoulos, George D.
Sirulnik, Andres
Chaudhry, Aafia
Ambati, Srikanth R.
Topp, Max S.
BLOOD, 2020, 136
[28] An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma
Falchi, Lorenzo
Ferrajoli, Alessandra
Jacobs, Ira
Nava-Parada, Pilar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (08) : 508 - +
[29] Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma
Hotta, T
ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (04) : 275 - 279
[30] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Bell, Jill A.
Cherepanov, Dasha
Revicki, Dennis
Speck, Rebecca M.
Swett, Laura
Stumpo, Kate
Rong, Yuanxin
Gordon, Leo I.
QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68

← 1 2 3 4 5 →